Argenx Follows up Phase III Success with Giant €785M Global Offering
Authera lands collaborative agreement with argenx – Inven2
Corporate Presentation June 2023
ITP Support Association - Press release from argenx, they are evaluating: Efgartigimod in ITP: Phase 3 ADVANCE registrational trial initiated evaluating approximately 150 primary ITP patients dosed with 10mg/kg IV efgartigimod for
Argenx's Potential Blockbuster Gets FDA Nod for Autoimmune Disease
argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis | Business Wire
argenx | News
Press release on the reopening of trading in ARGENX | FSMA
Argenx gets FDA nod for first subcutaneous gMG therapy | pharmaphorum
Latest Healthcare and Pharma Press Release | Latest Healthcare News
FUJIFILM Diosynth Biotechnologies enters into an Agreement with Argenx
argenx | News
Argenx Files for FDA Approval of Efgartigimod for Generalized MG
Genmab expands immunology reach in argenx pact
Argenx: Next Phase Of Growth With Efgartigimod And ARGX-117 (NASDAQ:ARGX) | Seeking Alpha
argenx Announces U.S. Food and Drug Administration Approval
ELITE 2023 Marketing Team VYVGART Brand Launch Team of argenx | PM360
argenx Reports Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy | Argenx
argenx | News
ARGENX SE - VYVGART for Generalized Myasthenia Gravis VYVGART and VYVGART Hytrulo are indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive
Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology | Business Wire
Positive Topline Data Reported from argenx's ADHERE Study of VYVGART® Hytrulo with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
Press Releases | Argenx
argenx on X: "Today we announced the continuation of our chronic inflammatory demyelinating polyneuropathy (CIDP) program following interim analysis of the Phase 2/3 ADHERE trial. Learn more here: https://t.co/0vgXZk0o0u https://t.co/iv5KRcJfH8" / X
argenx Receives the EMA's CHMP Positive Opinion of Efgartigimod for Generalized Myasthenia Gravis
argenx | News
